Phaarmasia Limited (BOM:523620)
89.55
-0.45 (-0.50%)
At close: Sep 25, 2026
Phaarmasia Revenue
Phaarmasia had revenue of 82.83M INR in the quarter ending June 30, 2026, with 20.51% growth. This brings the company's revenue in the last twelve months to 486.17M, up 111.84% year-over-year. In the fiscal year ending March 31, 2026, Phaarmasia had annual revenue of 472.08M with 93.72% growth.
Revenue (ttm)
486.17M
Revenue Growth
+111.84%
P/S Ratio
1.26
Revenue / Employee
10.34M
Employees
47
Market Cap
611.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 472.08M | 228.39M | 93.72% |
| Mar 31, 2025 | 243.69M | -62.25M | -20.35% |
| Mar 31, 2024 | 305.93M | 31.04M | 11.29% |
| Mar 31, 2023 | 274.90M | 102.74M | 59.68% |
| Mar 31, 2022 | 172.16M | -31.79M | -15.59% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.32B |
| ANG Lifesciences India | 835.87M |
| Source Natural Foods and Herbal Supplements | 796.24M |
| Shelter Pharma | 731.34M |
| Onyx Biotec | 694.69M |
| Amwill Health Care | 454.92M |
| Biofil Chemicals and Pharmaceuticals | 346.26M |
| Cian Healthcare | 282.99M |